Literature DB >> 16405554

A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma.

Keiji Hirata1, Shuichi Kanemitsu, Yoshifumi Nakayama, Naoki Nagata, Hideaki Itoh, Hideo Ohnishi, Hideki Ishikawa, Yoichi Furukawa.   

Abstract

BACKGROUND: One of the clinical features of hereditary nonpolyposis colorectal cancer (HNPCC) is a high incidence of multiple primary neoplasms arising in various organs including the gastrointestinal and genitourinary tracts. Among extracolonic tumors, a limited number of soft tissue sarcomas associated with HNPCC have been reported, and the mechanism underlying liposarcoma in HNPCC patients remains unclear. AIM: We herein report the case of a HNPCC patient with liposarcoma, with the goal of elucidating the involvement of a mismatch repair deficiency in the tumor. METHODS AND
RESULTS: A 40-yr-old Japanese patient, who had a past history of adenocarcinoma of the rectum and transitional cell carcinoma of the urinary bladder, developed a liposarcoma in his left thigh. Although his family history did not fulfill the revised Amsterdam criteria, his blood sample was subjected to genetic testing. Direct sequencing of the genomic DNA from the blood identified an AT deletion at codon 677 in exon 13 of hMSH2, a pathogenic mutation that has not been reported before. The expression of MSH2 in the liposarcoma and rectal cancer of the patient was analyzed by immunohistochemistry, which revealed loss of MSH2 expression in the tumors. To investigate whether the loss of MSH2 was a common feature of liposarcoma, we examined the MSH2 expression in an additional two sporadic liposarcomas, both of which were stained with anti-MSH2 antibody.
CONCLUSION: We identified a novel pathogenic germline mutation of MSH2 in an HNPCC patient. Since an immunohistochemical analysis showed no nuclear staining for MSH2 protein in the liposarcoma as well as the rectal cancer, the loss of wild-type MSH2 protein was thus considered to possibly play a role in the development of liposarcoma in HNPCC patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16405554     DOI: 10.1111/j.1572-0241.2005.00308.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  14 in total

1.  Muir-Torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field.

Authors:  Masato Yozu; Pennie Symmans; Michael Dray; Jennifer Griffin; Catherine Han; Daniel Ng; Susan Parry; Kp Wong
Journal:  Virchows Arch       Date:  2013-01-09       Impact factor: 4.064

2.  Synchronous recurrence of concurrent colon adenocarcinoma and dedifferentiated liposarcoma.

Authors:  Eric E Jung; F Scott Heinemann; Colt A Egelston; Jennifer Wang; Raphael E Pollock; Peter P Lee; William W Tseng
Journal:  BMJ Case Rep       Date:  2019-05-13

3.  Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer.

Authors:  Masataka Adachi; Kouji Banno; Megumi Yanokura; Miho Iida; Kanako Nakamura; Yuya Nogami; Kiyoko Umene; Kenta Masuda; Iori Kisu; Arisa Ueki; Akira Hirasawa; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-11-20

Review 4.  Soft tissue sarcoma and the hereditary non-polyposis colorectal cancer (HNPCC) syndrome: formulation of an hypothesis.

Authors:  E Urso; M Agostini; S Pucciarelli; C Bedin; E D'angelo; C Mescoli; A Viel; I Maretto; I Mammi; D Nitti
Journal:  Mol Biol Rep       Date:  2012-07-11       Impact factor: 2.316

5.  Malignant fibrous histiocytoma is a rare Lynch syndrome-associated tumor in two German families.

Authors:  Angela Brieger; Knut Engels; Dieter Schaefer; Guido Plotz; Stefan Zeuzem; Jochen Raedle; Joerg Trojan
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

6.  Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrum.

Authors:  Mef Nilbert; Christina Therkildsen; Anja Nissen; Måns Akerman; Inge Bernstein
Journal:  Fam Cancer       Date:  2009-01-08       Impact factor: 2.375

Review 7.  Epimutation and cancer: a new carcinogenic mechanism of Lynch syndrome (Review).

Authors:  Kouji Banno; Iori Kisu; Megumi Yanokura; Kosuke Tsuji; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Wataru Yamagami; Hiroyuki Nomura; Eiichiro Tominaga; Nobuyuki Susumu; Daisuke Aoki
Journal:  Int J Oncol       Date:  2012-06-25       Impact factor: 5.650

8.  A novel pathogenic MLH1 missense mutation, c.112A > C, p.Asn38His, in six families with Lynch syndrome.

Authors:  Els van Riel; Margreet Gem Ausems; Frans Bl Hogervorst; Irma Kluijt; Marielle E van Gijn; Jeanne van Echtelt; Karen Scheidel-Jacobse; Eric Fam Hennekam; Rein P Stulp; Yvonne J Vos; G Johan A Offerhaus; Fred H Menko; Johan Jp Gille
Journal:  Hered Cancer Clin Pract       Date:  2010-08-12       Impact factor: 2.857

9.  Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.

Authors:  R S van der Post; L A Kiemeney; M J L Ligtenberg; J A Witjes; C A Hulsbergen-van de Kaa; D Bodmer; L Schaap; C M Kets; J H J M van Krieken; N Hoogerbrugge
Journal:  J Med Genet       Date:  2010-07       Impact factor: 6.318

10.  Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum.

Authors:  Rein P Stulp; Johanna C Herkert; Arend Karrenbeld; Bart Mol; Yvonne J Vos; Rolf H Sijmons
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.